Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl
Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced
Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast
Crisis, or Acute Lymphoblastic Leukemia.